To better elucidate the socioeconomic and racial differences in women who received postmastectomy radiation therapy with or without a chest wall boost, the records from 4747 women included in the California Cancer Registry were reviewed. Poor and Hispanic women were more likely to receive a chest wall boost than were more affluent and non-Hispanic women. Introduction: Healthcare disparities in breast cancer treatment have been well documented. We investigated the socioeconomic status (SES) and racial factors in women with locally advanced breast cancer from the California Cancer Registry who had received postmastectomy radiation therapy (PMRT) with or without a chest wall boost (CWB). women. Also, women of low SES were more likely to receive a CWB than women of high SES (HR, 0.74; 95% CI, 0.64-0.86). Conclusion: We found that poor and Hispanic women were more commonly treated with a CWB than were more affluent and non-Hispanic women with a similar cancer stage, cancer biology, and treatment paradigm. Breast Cancer, Vol. 15, No. 3, Published by Elsevier Inc.
Introduction
Racial disparities in the treatment of breast cancer have been well documented. Compared with white women, a lower incidence and greater mortality rates have been demonstrated in non-Hispanic black women, and Hispanic women have been shown to have both a lower incidence and a lower mortality rate. 1, 2 The rate of breast conservation surgery versus mastectomy in women with appropriate cancer staging and the rate of systemic therapy reception have also been lower for black and Hispanic women than for white women. [3] [4] [5] [6] [7] Socioeconomic status (SES) disparities and limited access to healthcare could significantly confound the racial differences in biology or the natural history of breast cancer. [8] [9] [10] Census tracts with greater poverty status are more likely to display significant differences in breast cancer mortality in both black and Hispanic women. 11 A national cohort study of patients with breast cancer found that uninsured women, Medicaid enrollees, and younger Medicare beneficiaries were less likely to receive definitive locoregional therapy and adjuvant systemic treatment compared with privately insured women. 12 Prospective randomized trials have demonstrated that postmastectomy radiation therapy (PMRT) improves breast cancer survival and overall survival and that the area at the greatest risk of local recurrence is the chest wall (5%-15%). [13] [14] [15] [16] [17] [18] The risk factors that can contribute to this local failure include young age, lymphovascular invasion (LVSI), triple negative status, a poor response to neoadjuvant chemotherapy, inflammatory breast cancer from an inflammatory presentation, 4 positive nodes, and positive surgical margins. 18, 19 Landmark trials did not treat women with focal dose escalation to the mastectomy scar, known as a chest wall boost (CWB), and no additional prospective data are available on the benefit of a CWB or specifications regarding when it should be used. [19] [20] [21] Furthermore, a CWB has shown to result in increased skin toxicity, leading to early cessation of the treatment course. 22 Thus, controversy and practice pattern variability exist in the use of a radiation CWB. Some centers have reported consistent use of a CWB with PMRT 23, 24 and improved local recurrence rates. 24 The purpose of the present study was to evaluate, using a population-based cohort from the California Cancer Registry (CCR), the influence of race and SES in the use of a CWB after PMRT for breast cancer.
Patients and Methods

Data
A retrospective observational study of patients with first primary, invasive breast cancer diagnosed from 2005 to 2009, who had undergone mastectomy followed by PMRT, was conducted using the CCR. This statewide population-based database includes 3 registries (Greater Bay Area, Los Angeles, and Greater California) that are a part of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. The database has had standardized collection and quality control protocols since 1988. The CCR has demographic and tumor information obtained from patients' medical records. The data available included age and marital status at diagnosis; race/ ethnicity; tumor size; lymph node involvement; cancer stage according to the American Joint Committee on Cancer (AJCC); tumor grade; histologic type; laterality; focality; expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2/neu (HER2); other cancer treatments, including surgery and radiation; and vital status at the last contact or vital status record linkage. Clinical Breast Cancer June 2015 -213
Patients
The medical records of women with invasive breast cancer were reviewed and stratified according to whether a CWB had been received after PMRT. The race and ethnicity groups were defined as non-Hispanic white (NHW), non-Hispanic black (NHB), nonHispanic Asian/Pacific Islander (API), and Hispanic (HSP). Race and Hispanic ethnicity were determined from data abstracted from the medical records. HSP ethnicity was further enhanced using the North American Association of Central Cancer Registries Hispanic Identification Algorithm. 25 We did not further classify HSP ethnicity by the patients' country of origin. Low, medium, and high SES were defined using well-used and previously described method 26 of geographic area-based composite SES measures using specific variable quintiles from the 2000 US census.
Statistical Analysis
Race/ethnicity and SES between the cohorts were analyzed using the c 2 test of independence to compare differences in the individual-and clinical-level variables between patients who received CWB and those who did not. Adjusting for potential confounders, multivariate logistic regression models were used to identify the predictors of CWB reception, reported as odds ratios and 95% confidence intervals; significance was set at P < .05, and all tests were 2-sided. The geographic distribution of CWB reception versus no CWB reception was assessed by California hospital referral region (HRR) 27 and compared with the geographic distribution of HSP ethnicity and poverty by California county using a Pearson correlation coefficient matrix. 28 
Results
Overall, our cohort consisted of 4747 women who had received PMRT. Most women (32%) were aged 60 years; 29% and 26% were in their 40s and 50s. Of the 4747 women, 56% had stage III, 35% stage II, and 5% stage I, with 53% of the patients having 2 to 5 cm tumors and 49% having grade 3 or 4 disease. ER positivity was confirmed in 65% and PR positivity in 61%; only 26% were HER2 þ (overall, 60% with luminal A tumors) ( Table 1 ). The median follow-up period was 43.6 months. Of the 4747 women, 2686 (57%) received a CWB and 2061 (43%) did not. Of the participants, 59% were NHW, 6% NHB, 15% API, and 21% HSP. The SES was high for 51%, middle for 20%, and low for 29% (Table 1 ). The distribution of race among those with a high versus low SES was 69% versus 40% for NHWs, 3% versus 11% for NHBs, 17% versus 11% for APIs, and 11% versus 38% for HSPs, respectively. The distribution of SES among those of NHW, NHB, API, and HSP race/ethnicity was high for 60%, 26%, 59%, and 26%, middle for 20%, 18%, 20%, and 21%, and low for 19%, 56%, 21%, and 53%, respectively. Of the NHW women with a high, medium, or low SES, 54%, 58%, and 58% received a CWB compared with 55%, 58%, and 69% of all HSP women, respectively ( Figure 1 ). Univariate analysis revealed that CWB reception was associated with race/ethnicity (P < .001), SES (P < .001), tumor size (P ¼ .038), tumor grade (P ¼ .033), HER2 status (P ¼ .015), AJCC stage (P ¼ .001), number of nodes examined (P ¼ .001), and number of nodes positive (P ¼ .037) ( Table 2) . No significant differences were found between those who had received a CWB and those who did not with respect to age, urbanization level, laterality, ER/PR status, tumor subtype, chemotherapy, or hormonal therapy.
On multivariate analysis, HSP ethnicity (vs. NHW, NHB, and API, P ¼ .01, P ¼ .001, and P ¼ .003, respectively) and low SES status (vs. high, P < .001) retained a strong significant association with CWB reception, while for stage, grade, number of positive nodes, number of nodes examined, and HER2 status (Table 3) . Other factors also independently predicting reception of a CWB on multivariate analysis were stage III disease (vs. stage II, P ¼ .028) and 10 nodes examined (vs. < 10, P ¼ .035). Substantial geographic heterogeneity in CWB prescription was present among the HRRs (Table 4 ) that did not correlate with ethnicity (correlation coefficient, r ¼ 0.36, P ¼ .08) or poverty (r ¼ 0.16, P ¼ .44).
Discussion
The present large, observational, retrospective study of California women with locally advanced breast cancer who had undergone mastectomy and PMRT found that low SES and HSP ethnicity were independently predictive of reception of a CWB. We also explored the potential confounding factors that might have contributed to this disparity. 
Disparities in Selection of Chest Wall Boost RT
The clinical and pathologic factors that can influence a treating physician to deliver a CWB include positive mastectomy margins, LVSI, previous regional failure, triple-negative tumor marker status, a poor response to neoadjuvant chemotherapy, stage T4 disease, age < 45 years, large tumor size, hormone receptor negative status, 4 of positive nodes, and inflammatory breast cancer. 24, [29] [30] [31] [32] [33] [34] [35] [36] Our multivariate analysis also identified the number of nodes examined ( 10) and stage III as independent predictors of receipt of a CWB. Practice patterns and limited access to alternate medical care could also be influential, if, for example, providers practicing in predominantly HSP or low SES geographic regions have maintained any historical CWB-favoring prescription precedence of the institutions at which they trained. We could not explore the influence of margin status or LVSI on the receipt of a CWB because of the limitations of the CCR database.
HSP ethnicity and low SES remained independently predictive of use of a CWB in our multivariate logistic regression analysis, which controlled for all the aforementioned confounders, except for LVSI and positive margins. These latter 2 parameters were not collected within the CCR for the diagnosis years of our cohort. Although we could not control for this potential confounding influence, we found that all other discoverable risk factors for locoregional recurrence, cumulatively, did not negate the association between race/ethnicity and SES and the reception of a CWB, which were the strongest of all the associations (Table 3) .
The correlation between the geographic distribution of the physician CWB prescription patterns and ethnic and socioeconomic density was also considered to be a potential confounder of our findings. This was evaluated by stratifying patients treated with and without a CWB by California HRR in relation to the US Census Bureau statistics of the HSP population and poverty level density by county of residence. We found significant variations in the CWB delivery geographically, but this did not correlate with the geographic distribution of HSP ethnicity or impoverishment (Table 4) . Although a percentage of patients might have traveled outside their county of residence for treatment, the comparison 
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Clinical Breast Cancer June 2015 -215 provides a crude assessment that the heterogeneity of the prescription pattern by location does not closely mimic that of SES or ethnicity. It is, therefore, less likely that the increased rates of CWB observed for poor and Hispanic women can be explained by the geographic variability in the practice patterns or proximity of poor and HSP women to providers who routinely prescribe a CWB for all patients who have undergone PMRT. Physician bias toward HSP and poor women could also have contributed to increased rates of CWB reception. We have anecdotally observed a propensity of physicians to prescribe alternative treatments to patients perceived as incapable of compliant follow-up. We have coined the term "likely-lost effect" to define this phenomenon. Women of HSP ethnicity and low SES might have more commonly been prescribed a CWB to maximize the theoretical benefit of escalated treatment aimed at preventing missed opportunities for early salvage treatment of recurrent disease if patients were noncompliant to follow-up examinations.
The likely-lost effect might bias provider decision-making in other scenarios more likely to affect oncologic outcomes and quality of life than the decision to prescribe a CWB. For example, a patient might be denied a time-intensive definitive radiation regimen in favor of a shorter palliative regimen, be treated with less-intense chemotherapy requiring fewer laboratory studies or conveying less risk, or be offered early treatment instead of an equally appropriate watch-and-wait strategy if the patient has been deemed unlikely to comply with close monitoring. Awareness of this potential bias might encourage providers to optimize support services to address barriers to compliant follow-up and discourage hasty racial or economic profiling of patients. Discrepant follow-up lengths between the CWB and no-CWB cohorts and when stratified by race/ ethnicity and SES were hypothesized but not assessable. The CCR uses a passive follow-up mechanism to gauge survival that is independent of provider, often using death certificates and other publically available administrative databases. It does not collect the patient-with-provider follow-up duration.
However, an association between race/ethnicity or SES and follow-up compliance has not been definitively demonstrated in prospective studies. Small retrospective studies 3, 36, 37 have reported conflicting results that race/ethnicity might have no association with patient-kept appointments. 38 A number of other barriers to compliant follow-up, such as finance, transportation, distress management, social support, language barriers, and so forth, might influence patients' ability to be compliant with follow-up examinations 39 and should be simultaneously considered before treatment escalation, along with the increased risk of acute and late toxicity.
22
A major strength of our study was its population base-breast cancer cases from the entire state of California. The CCR has been a statewide database since 1988 and is one of the largest cancer registries in the world. The registry is also a part of the SEER program through contracts with 3 regional registries within California and meets all the quality and completeness standards of the National Cancer Institute's SEER program and those of the National Association of Central Cancer Registries. The study included a large number of patients (n ¼ 4747), providing statistical power for most of the analyses. The major limitation was the lack of data regarding margin status and LVSI.
Conclusion
Poor women of any race and HSP women were more commonly treated with a CWB compared with more affluent and nonHispanic women with a similar cancer stage, biology, and treatment paradigm. Our investigation revealed a previously unreported provider bias to treat poor and HSP women with more escalated treatment. Variations in the geographic prescription patterns and the "likely-lost effect" could potentially have contributed to this disparity.
Clinical Practice Points
The use of a CWB after PMRT remains controversial. SES status and racial disparities exist in the natural progression of breast cancer, disease-specific mortality, and the type of therapy received. A population-based examination of the prescription practices found that a low SES and HSP ethnicity were independently predictive of receipt of a CWB. The likely-lost effect might be a bias in provider decision-making that could partially account for the prescription differences.
